USPTO serial 86364754
SOCTEC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 19, 2018
- Examiner
- HENRY, NAKIA D
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.
Need help with SOCTEC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
SAINT-QUENTIN-FALLAVIER, FR
4132 Muttenz, CH
4132 Muttenz, CH
4132 Muttenz, CH
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Molly Buck Richard
Molly Buck Richard RICHARD LAW GROUP13355 Noel Rd, Suite 1350DALLAS, TX 75240United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceuticals having a self-orienting effect, namely, orally delivered pharmaceuticals with modified time release into the gastrointestinal system; gastro retentive pharmaceuticals; self orienting pharmaceuticals in the form of capsules, namely, capsules consisting of segments of varied functions and absorption rates, resulting in controlled release into the gastrointestinal tract; Gastrointestinal drug delivery preparations for medical, surgical and biological purposes; chronotherapy-focused tablets, analgesics; Medicines for treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; medicinal preparations for treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; capsules for the release of colonic drug delivery; pharmaceuticals for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders, medical and veterinary preparations for body slimming purposes; capsules, suppositories, tablets and pills for pharmaceutical, medical and veterinary purposes for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pre-filled vials containing medical diagnostic reagents; exclude goods being related to the treatment of respiratory diseases ] | SECTION 8 - CANCELLED | — |
| 010 | [ inhalers for medical purposes; injection apparatus, instruments and devices, namely, medical apparatus in the nature of an infusion injection device for administering drugs; apparatus, instruments and devices, namely, automated drug delivery systems for storing and dispensing medical, surgical and veterinary preparations, capsules, powders, tablets and pills; instruments and apparatus for the administration of self-orientation therapy and prophylaxis preparations and substances, namely, gastrointestinal drug delivery systems, syringes and fluid injectors for medical purposes; exclude goods being related to the treatment of respiratory diseases ] | SECTION 8 - CANCELLED | — |
| 042 | Scientific and technological services, namely, custom design exclusively in the pharmaceuticals and medical fields; design services exclusively in the pharmaceuticals and medical fields; drug development and custom design of pharmaceuticals and medical goods; exclude services in the field of inhalation technology | ACTIVE | — |
| 044 | [ Medical services; veterinary services; hygienic care for human beings or animals; medical analysis for the diagnosis and treatment of persons treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmacy advice; provision of information relating to medical, surgical and veterinary matters online from a computer database or over the Internet; exclude services in the field of inhalation technology ] | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SKYEPHARMA PRODUCTION S.A.S.
- Other trademarks owned by Jagotec AG
- Other trademarks owned by Jagotec AG
- Other trademarks owned by Jagotec AG
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SOCTEC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 22, 2025 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jan 22, 2025 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jan 21, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 29, 2024 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Aug 22, 2024 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 19, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jun 19, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 29, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 3, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 3, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 14, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 26, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 13, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 13, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 12, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 12, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 12, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 27, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 3, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 2, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Oct 31, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 31, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 31, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 31, 2017 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Oct 31, 2017 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Oct 31, 2017 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| May 9, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 14, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 14, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 22, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 7, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 31, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 31, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 31, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 31, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 31, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 15, 2016 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 15, 2016 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 15, 2016 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 20, 2016 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jul 14, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 14, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 14, 2016 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 20, 2016 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 20, 2016 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 20, 2016 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 29, 2015 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 25, 2015 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 25, 2015 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 25, 2015 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 8, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 8, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 1, 2015 | ALIE | ASSIGNED TO LIE | — |
| May 26, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 26, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 25, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 21, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 15, 2014 | NWAP | NEW APPLICATION ENTERED | — |